| abstract |
The present invention is to provide a novel heterocyclic compound of the formula [I]: n n n n n n n n n n n n wherein R 1 is a halogen, nitro, an alkyl, etc.; R 2 is hydrogen, an alkyl, etc.; Ring A is 2-oxo-4-imidazolin-3,4-diyl, etc.; Ring B is a cycloalkyl, monocyclic saturated heterocyclic group; X is CH, N; Y is a single bond, CO, SO 2 ; Z is O, NH, etc.; and Ring C is an aryl, a heterocyclic group,n nor a pharmaceutically acceptable salt thereof, which is useful as a p38 MAP kinase inhibitor. |